WHO ICTRP trial
Efficacy and safety of ANAkinra during Adult « COVID-19 » with Aggravating…
EUCTR2020-001734-36-FR · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2020-001734-36-FR |
|---|---|
| Public title | Efficacy and safety of ANAkinra during Adult « COVID-19 » with Aggravating respiratory symptoms: a multicenter open-label controlled randomized trial |
| Scientific title | Efficacy and safety of ANAkinra during Adult « COVID-19 » with Aggravating respiratory symptoms: a multicenter open-label controlled randomized trial - ANACONDA-COVID-19 |
| Primary sponsor | CHRU de TOURS |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): yes Therapeutic use (Phase IV): no |
| Countries | France |
| Conditions | COVID-19 infection;Therapeutic area: Diseases [C] - Virus Diseases [C02] |
| Interventions | Trade Name: Kineret Product Name: Kineret Pharmaceutical Form: Injection |
| Registration date | Apr 15, 2020 |
| Target size | 240 |
| Secondary IDs | DR200111 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: